Marisa Wexler, MS,  senior science writer—

LYT-100, PureTech Health’s oral treatment candidate for idiopathic pulmonary fibrosis (IPF), was well tolerated among healthy older adults at doses leading to much higher amounts of active medication in the body than the approved dose of Esbriet (pirfenidone). That’s according to new data from Phase 1 clinical…

Proteins called histones can trigger lung fibrosis (scarring) by prompting platelets, cell fragments involved in blood clotting, to release a signaling molecule called transforming growth factor beta 1 (TGFB1), a new study found. TGFB1, in turn, blocks the production of interleukin-27 (IL-27), a signaling molecule that normally helps to limit…

Zelasudil, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s now being tested in clinical trials, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA). The FDA awards this designation to therapies with the potential to substantially improve care for people with rare diseases,…

Trevi Therapeutics is planning to launch two new clinical trials this fall to test Haduvio (nalbuphine extended-release tablets) for chronic cough in people with idiopathic pulmonary fibrosis (IPF). One of the trials will be a Phase 2b study to identify the best dose of the medication for…

The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking the approval of Ofev (nintedanib) for children ages 6 to 17 with fibrosing interstitial lung diseases (ILDs). If approved, Ofev would become the first and only therapy available to treat children with fibrosing ILDs, according…

A three-protein signature can be used to differentiate between idiopathic pulmonary fibrosis (IPF) and other lung disorders and may be a noninvasive biomarker of the rare disease, according to a new study. While the scientists stressed that further research will be needed to validate the…

The Phase 3 REBUILD clinical trial, which tested Bellerophon Therapeutics‘ inhaled nitric oxide therapy INOpulse in people with pulmonary fibrosis at risk of developing pulmonary hypertension, failed to meet its primary or secondary goals, according to recent top-line data. “The REBUILD study did not match the outcomes we…

The first participant has been dosed in a clinical trial testing the experimental anti-fibrotic therapy BBT-877 in people with idiopathic pulmonary fibrosis (IPF). The milestone was announced by BBT-877’s developer Bridge Biotherapeutics, which initiated the trial late last year. “The first patient dosing of BBT-877 marks an…

ZEPHYRUS-2, the second Phase 3 clinical trial testing the experimental therapy pamrevlumab in people with idiopathic pulmonary fibrosis (IPF), has finished recruiting patients, according to its developer FibroGen. “We are pleased to announce the completion of enrollment for our second Phase 3 study of pamrevlumab in IPF,” Mark…

Treatment with Nuformix’s experimental therapy NXP002 reduced markers of fibrosis, or tissue scarring, in a laboratory model of idiopathic pulmonary fibrosis (IPF), according to new data announced by the company. Adding NXP002 to standard-of-care IPF treatments — Esbriet (pirfenidone) and Ofev (nintedanib) — led to a…